Philippe Chanson

List of Publications by Year in Descending Order

261 papers	14,724 citations	71 h-index	111 g-index
295 ext. papers	17,374 ext. citations	6.6 avg, IF	6.37 L-index

#	Paper	IF	Citations
261	Treatment of acromegaly has substantial effects on body composition: a long-term follow-up study. *European Journal of Endocrinology*, **2021**, 186, 173-181	6.5	3
260	Consensus on diagnosis and management of Cushing disease: a guideline update. *Lancet Diabetes and Endocrinology,the*, **2021**, 9, 847-875	18.1	48
259	Pituitary adenoma in patients with multiple endocrine neoplasia type 1: a cohort study. *European Journal of Endocrinology*, **2021**, 185, 863-873	6.5	2
258	Cost-Utility of Acromegaly Pharmacological Treatments in a French Context. *Frontiers in Endocrinology*, **2021**, 12, 745843	5.7	1
257	Loss of KDM1A in GIP-dependent primary bilateral macronodular adrenal hyperplasia with Cushing syndrome: a multicentre, retrospective, cohort study. *Lancet Diabetes and Endocrinology,the*, **2021**, 9, 813-824	18.1	5
256	Clinically non-functioning pituitary adenomas. *Presse Medicale*, **2021**, 50, 104086	2.2	0
255	Outcome of pituitary hormone deficits after surgical treatment of nonfunctioning pituitary macroadenomas. *Endocrine*, **2021**, 73, 166-176	4	3
254	Blood microbiota and metabolomic signature of major depression before and after antidepressant treatment: a prospective case-control study. *Journal of Psychiatry and Neuroscience*, **2021**, 46, E358-E368	4.5	4
253	Diabetes Increases Severe COVID-19 Outcomes Primarily in Younger Adults. *Journal of Clinical Endocrinology and Metabolism*, **2021**, 106, e3364-e3368	5.6	3
252	Pituitary Society Delphi Survey: An international perspective on endocrine management of patients undergoing transsphenoidal surgery for pituitary adenomas. *Pituitary*, **2021**, 1	4.3	2
251	International Multicenter Validation Study of the SAGIT Instrument in Acromegaly. *Journal of Clinical Endocrinology and Metabolism*, **2021**, 106, 3555-3568	5.6	1
250	The heart in growth hormone (GH) deficiency and the cardiovascular effects of GH. *Annales DlEndocrinologie*, **2021**, 82, 210-213	1.7	3
249	Cardiovascular complications of acromegaly. *Annales DlEndocrinologie*, **2021**, 82, 206-209	1.7	4
248	Pegvisomant in combination or pegvisomant alone after failure of somatostatin analogs in acromegaly patients: an observational French ACROSTUDY cohort study. *Endocrine*, **2021**, 71, 158-167	4	4
247	McCune-Albright Syndrome in Clinical Practice. *Endocrinology*, **2021**, 377-386	0.1	
246	Sensitivity and specificity of the macimorelin test for diagnosis of AGHD. *Endocrine Connections*, **2021**, 10, 76-83	3.5	4
245	Endocrinological diagnosis and treatment of TSH-secreting pituitary adenomas **2021**, 245-260		

244	Clinical aspects of multiple endocrine neoplasia type 1. *Nature Reviews Endocrinology*, **2021**, 17, 207-224	15.2	15
243	Pituitary Neoplasm Nomenclature Workshop: Does Adenoma Stand the Test of Time?. *Journal of the Endocrine Society*, **2021**, 5, bvaa205	0.4	14
242	Apoplexy of microprolactinomas during pregnancy: report of five cases and review of the literature. *European Journal of Endocrinology*, **2021**, 185, 99-108	6.5	4
241	Pegvisomant treatment in acromegaly in clinical practice: Final results of the French ACROSTUDY (312 patients). *Annales DlEndocrinologie*, **2021**, 82, 582-589	1.7	2
240	Epicardial and Pericardial Adiposity Without Myocardial Steatosis in Cushing Syndrome. *Journal of Clinical Endocrinology and Metabolism*, **2021**, 106, 3505-3514	5.6	0
239	Reference values for IGF-I serum concentration in an adult population: use of the VARIETE cohort for two new immunoassays. *Endocrine Connections*, **2021**, 10, 1027-1034	3.5	0
238	Somatostatin receptor ligands induce TSH deficiency in thyrotropin-secreting pituitary adenoma. *European Journal of Endocrinology*, **2021**, 184, 1-8	6.5	3
237	McCune-Albright Syndrome in Clinical Practice. *Endocrinology*, **2021**, 1-10	0.1	
236	Italian Association of Clinical Endocrinologists (AME) and Italian AACE Chapter Position Statement for Clinical Practice: Acromegaly - Part 1: Diagnostic and Clinical Issues. *Endocrine, Metabolic and Immune Disorders - Drug Targets*, **2020**, 20, 1133-1143	2.2	2
235	The 2016-2019 ImmunoTOX assessment board report of collaborative management of immune-related adverse events, an observational clinical study. *European Journal of Cancer*, **2020**, 130, 39-50	7.5	17
234	Multivariable Prediction Model for Biochemical Response to First-Generation Somatostatin Receptor Ligands in Acromegaly. *Journal of Clinical Endocrinology and Metabolism*, **2020**, 105,	5.6	11
233	Non-invasive Diagnostic Strategy in ACTH-dependent Cushing Syndrome. *Journal of Clinical Endocrinology and Metabolism*, **2020**, 105,	5.6	27
232	How can we minimise the use of regular oral corticosteroids in asthma?. *European Respiratory Review*, **2020**, 29,	9.8	15
231	Pituitary Stalk Enlargement in Adults. *Neuroendocrinology*, **2020**, 110, 809-821	5.6	2
230	Transsphenoidal resection for pituitary adenoma in elderly versus younger patients: a systematic review and meta-analysis. *Acta Neurochirurgica*, **2020**, 162, 1297-1308	3	4
229	Italian Association of Clinical Endocrinologists (AME) and Italian AACE Chapter Position Statement for Clinical Practice: Acromegaly - Part 2: Therapeutic Issues. *Endocrine, Metabolic and Immune Disorders - Drug Targets*, **2020**, 20, 1144-1155	2.2	2
228	Congenital hypogonadotropic hypogonadism/Kallmann syndrome is associated with statural gain in both men and women: a monocentric study. *European Journal of Endocrinology*, **2020**, 182, 185	6.5	8
227	Central diabetes insipidus and pituitary stalk thickening in adults: distinction of neoplastic from non-neoplastic lesions. *European Journal of Endocrinology*, **2020**, 181, 95-105	6.5	4

226	Efficacy and safety of dopamine agonists in patients treated with antipsychotics and presenting a macroprolactinoma. *European Journal of Endocrinology*, **2020**, 183, 221-231	6.5	4
225	Hypertension in Acromegaly. *Updates in Hypertension and Cardiovascular Protection*, **2020**, 167-179	0.1	
224	Pituitary stalk thickening: neoplastic or not? - author reply to the letter by Wang et al. *European Journal of Endocrinology*, **2020**, 183, L23-L25	6.5	
223	Metastatic Potential and Survival of Duodenal and Pancreatic Tumors in Multiple Endocrine Neoplasia Type 1: A GTE and AFCE Cohort Study (Groupe d'Etude des Tumeurs Endocrines and Association Francophone de Chirurgie Endocrinienne). *Annals of Surgery*, **2020**, 272, 1094-1101	7.8	21
222	GnRH stimulation testing and serum inhibin B in males: insufficient specificity for discriminating between congenital hypogonadotropic hypogonadism from constitutional delay of growth and puberty. *Human Reproduction*, **2020**, 35, 2312-2322	5.7	4
221	Multidisciplinary management of acromegaly: A consensus. *Reviews in Endocrine and Metabolic Disorders*, **2020**, 21, 667-678	10.5	67
220	Cortisol and Aldosterone Responses to Hypoglycemia and Na Depletion in Women With Non-Classic 21-Hydroxylase Deficiency. *Journal of Clinical Endocrinology and Metabolism*, **2020**, 105,	5.6	1
219	An update on clinical care for pregnant women with acromegaly. *Expert Review of Endocrinology and Metabolism*, **2019**, 14, 85-96	4.1	11
218	Growth Hormone Response to Oral Glucose Load: From Normal to Pathological Conditions. *Neuroendocrinology*, **2019**, 108, 244-255	5.6	13
217	Contribution of functionally assessed GHRHR mutations to idiopathic isolated growth hormone deficiency in patients without GH1 mutations. *Human Mutation*, **2019**, 40, 2033-2043	4.7	3
216	Prolactin Assays and Regulation of Secretion: Animal and Human Data. *Contemporary Endocrinology* , **2019**, 55-78	0.3	2
215	Acromegaly. *Nature Reviews Disease Primers*, **2019**, 5, 20	51.1	128
214	National acromegaly registries. *Best Practice and Research in Clinical Endocrinology and Metabolism*, **2019**, 33, 101264	6.5	33
213	Hypermethylator Phenotype and Ectopic GIP Receptor in GNAS Mutation-Negative Somatotropinomas. *Journal of Clinical Endocrinology and Metabolism*, **2019**, 104, 1777-1787	5.6	10
212	68Ga-Exendin-4 PET/CT Detects Insulinomas in Patients With Endogenous Hyperinsulinemic Hypoglycemia in MEN-1. *Journal of Clinical Endocrinology and Metabolism*, **2019**, 104, 5843-5852	5.6	20
211	The epidemiology, diagnosis and treatment of Prolactinomas: The old and the new. *Best Practice and Research in Clinical Endocrinology and Metabolism*, **2019**, 33, 101290	6.5	43
210	Staging and managing patients with acromegaly in clinical practice: baseline data from the SAGIT validation study. *Pituitary*, **2019**, 22, 476-487	4.3	13
209	Other Pituitary Conditions and Pregnancy. *Endocrinology and Metabolism Clinics of North America*, **2019**, 48, 583-603	5.5	3

208	Use of radiotherapy after pituitary surgery for non-functioning pituitary adenomas. *European Journal of Endocrinology*, **2019**, 181, D1-D13	6.5	10
207	MON-244 GnRH Test Does Not Efficiently Discriminate Congenital Isolated Hypogonadotropic Hypogonadism from Constitutional Delay of Growth and Puberty in Males. *Journal of the Endocrine Society*, **2019**, 3,	0.4	78
206	Changes in metabolic parameters and cardiovascular risk factors after therapeutic control of acromegaly vary with the treatment modality. Data from the Bic re cohort, and review of the literature. *Endocrine*, **2019**, 63, 348-360	4	18
205	Signs and symptoms of acromegaly at diagnosis: the physician and the patient perspectives in the ACRO-POLIS study. *Endocrine*, **2019**, 63, 120-129	4	29
204	Genomic Alterations and Complex Subclonal Architecture in Sporadic GH-Secreting Pituitary Adenomas. *Journal of Clinical Endocrinology and Metabolism*, **2018**, 103, 1929-1939	5.6	31
203	Physiopathology, Diagnosis, and Treatment of Nonfunctioning Pituitary Adenomas. *Endocrinology*, **2018**, 93-128	0.1	0
202	Worse Health-Related Quality of Life at long-term follow-up in patients with Cushing disease than patients with cortisol producing adenoma. Data from the ERCUSYN. *Clinical Endocrinology*, **2018**, 88, 787-798	3.4	23
201	Preoperative medical treatment in Cushing syndrome: frequency of use and its impact on postoperative assessment: data from ERCUSYN. *European Journal of Endocrinology*, **2018**, 178, 399-409	6.5	24
200	missense mutation causes familial insulinomatosis and diabetes mellitus. *Proceedings of the National Academy of Sciences of the United States of America*, **2018**, 115, 1027-1032	11.5	45
199	Treatment of aggressive pituitary tumours and carcinomas: results of a European Society of Endocrinology (ESE) survey 2016. *European Journal of Endocrinology*, **2018**, 178, 265-276	6.5	118
198	Pituitary Apoplexy **2018**, 218-230		
197	A Consensus Statement on acromegaly therapeutic outcomes. *Nature Reviews Endocrinology*, **2018**, 14, 552-561	15.2	216
196	Macimorelin as a Diagnostic Test for Adult GH Deficiency. *Journal of Clinical Endocrinology and Metabolism*, **2018**, 103, 3083-3093	5.6	45
195	Physiopathology, Diagnosis, and Treatment of Nonfunctioning Pituitary Adenomas. *Endocrinology*, **2018**, 1-37	0.1	
194	Therapy for Acromegaly **2018**, 230-247		
193	Sex-Related Differences in Lactotroph Tumor Aggressiveness Are Associated With a Specific Gene-Expression Signature and Genome Instability. *Frontiers in Endocrinology*, **2018**, 9, 706	5.7	17
192	A randomised, open-label, parallel group phase 2 study of antisense oligonucleotide therapy in acromegaly. *European Journal of Endocrinology*, **2018**, 179, 97-108	6.5	23
191	Changes in the management and comorbidities of acromegaly over three decades: the French Acromegaly Registry. *European Journal of Endocrinology*, **2017**, 176, 645-655	6.5	89

190	Anti-Müllerian Hormone and Ovarian Morphology in Women With Isolated Hypogonadotropic Hypogonadism/Kallmann Syndrome: Effects of Recombinant Human FSH. *Journal of Clinical Endocrinology and Metabolism*, **2017**, 102, 1102-1111	5.6	39
189	Temozolomide treatment can improve overall survival in aggressive pituitary tumors and pituitary carcinomas. *European Journal of Endocrinology*, **2017**, 176, 769-777	6.5	79
188	Prolactinoma **2017**, 467-514		12
187	Classification of Patients With GH Disorders May Vary According to the IGF-I Assay. *Journal of Clinical Endocrinology and Metabolism*, **2017**, 102, 2844-2852	5.6	23
186	Diagnostic tests for Cushing's syndrome differ from published guidelines: data from ERCUSYN. *European Journal of Endocrinology*, **2017**, 176, 613-624	6.5	27
185	Cabergoline in acromegaly. *Pituitary*, **2017**, 20, 121-128	4.3	32
184	Acromegaly at diagnosis in 3173 patients from the Liège Acromegaly Survey (LAS) Database. *Endocrine-Related Cancer*, **2017**, 24, 505-518	5.7	110
183	Cabergoline Tapering Is Almost Always Successful in Patients With Macroprolactinomas. *Journal of the Endocrine Society*, **2017**, 1, 221-230	0.4	15
182	Group 2: Adrenal insufficiency: screening methods and confirmation of diagnosis. *Annales D'Endocrinologie*, **2017**, 78, 495-511	1.7	16
181	Group 5: Acute adrenal insufficiency in adults and pediatric patients. *Annales D'Endocrinologie*, **2017**, 78, 535-543	1.7	12
180	In-frame seven amino-acid duplication in arose over the last 3000 years, disrupts protein interaction and stability and is associated with gigantism. *European Journal of Endocrinology*, **2017**, 177, 257-266	6.5	11
179	Effects of cortisol on the heart: characterization of myocardial involvement in cushing's disease by longitudinal cardiac MRI T1 mapping. *Journal of Magnetic Resonance Imaging*, **2017**, 45, 147-156	5.6	7
178	Effectiveness of first-line pegvisomant monotherapy in acromegaly: an ACROSTUDY analysis. *European Journal of Endocrinology*, **2017**, 176, 213-220	6.5	18
177	Hypothalamic-Pituitary-Ovarian Axis Reactivation by Kisspeptin-10 in Hyperprolactinemic Women With Chronic Amenorrhea. *Journal of the Endocrine Society*, **2017**, 1, 1362-1371	0.4	16
176	Ten years' clinical experience with biosimilar human growth hormone: a review of efficacy data. *Drug Design, Development and Therapy*, **2017**, 11, 1489-1495	4.4	7
175	Adrenal GIPR expression and chromosome 19q13 microduplications in GIP-dependent Cushing's syndrome. *JCI Insight*, **2017**, 2,	9.9	25
174	Medical Treatment of Acromegaly with Dopamine Agonists or Somatostatin Analogs. *Neuroendocrinology*, **2016**, 103, 50-8	5.6	22
173	Mild pituitary phenotype in 3- and 12-month-old Aip-deficient male mice. *Journal of Endocrinology*, **2016**, 231, 59-69	4.7	11

172	Pitfalls for detecting interleukin-33 by ELISA in the serum of patients with primary Sjögren syndrome: comparison of different kits. *Annals of the Rheumatic Diseases*, **2016**, 75, 633-5	2.4	16
171	Very low frequency of germline GPR101 genetic variation and no biallelic defects with AIP in a large cohort of patients with sporadic pituitary adenomas. *European Journal of Endocrinology*, **2016**, 174, 523-30	6.5	32
170	SAGIT : clinician-reported outcome instrument for managing acromegaly in clinical practice--development and results from a pilot study. *Pituitary*, **2016**, 19, 39-49	4.3	37
169	Serum PTH reference values established by an automated third-generation assay in vitamin D-replete subjects with normal renal function: consequences of diagnosing primary hyperparathyroidism and the classification of dialysis patients. *European Journal of Endocrinology*, **2016**, 174, 315-23	6.5	22
168	AIP mutations impair AhR signaling in pituitary adenoma patients fibroblasts and in GH3 cells. *Endocrine-Related Cancer*, **2016**, 23, 433-43	5.7	16
167	Reference Values for IGF-I Serum Concentrations: Comparison of Six Immunoassays. *Journal of Clinical Endocrinology and Metabolism*, **2016**, 101, 3450-8	5.6	70
166	Prevalence of KISS1 Receptor mutations in a series of 603 patients with normosmic congenital hypogonadotrophic hypogonadism and characterization of novel mutations: a single-centre study. *Human Reproduction*, **2016**, 31, 1363-74	5.7	34
165	Diabetes insipidus and pregnancy. *Annales DlEndocrinologie*, **2016**, 77, 135-8	1.7	16
164	Germline Prolactin Receptor Mutation Is Not a Major Cause of Sporadic Prolactinoma in Humans. *Neuroendocrinology*, **2016**, 103, 738-45	5.6	13
163	Long-term results of the surgical management of insulinoma patients with MEN1: a Groupe d'Etude des Tumeurs Endocrines (GTE) retrospective study. *European Journal of Endocrinology*, **2015**, 172, 309-19	6.5	34
162	Therapy of endocrine disease: outcomes in patients with Cushing's disease undergoing transsphenoidal surgery: systematic review assessing criteria used to define remission and recurrence. *European Journal of Endocrinology*, **2015**, 172, R227-39	6.5	89
161	Pituitary MRI characteristics in 297 acromegaly patients based on T2-weighted sequences. *Endocrine-Related Cancer*, **2015**, 22, 169-77	5.7	56
160	Management of nonfunctioning pituitary incidentaloma. *Annales DlEndocrinologie*, **2015**, 76, 191-200	1.7	32
159	Clinical and genetic characterization of pituitary gigantism: an international collaborative study in 208 patients. *Endocrine-Related Cancer*, **2015**, 22, 745-57	5.7	119
158	Management of clinically non-functioning pituitary adenoma. *Annales DlEndocrinologie*, **2015**, 76, 239-47	1.7	94
157	Macroprolactinomas in children and adolescents: factors associated with the response to treatment in 77 patients. *Journal of Clinical Endocrinology and Metabolism*, **2015**, 100, 1177-86	5.6	58
156	Rapid control of severe neoplastic hypercortisolism with metyrapone and ketoconazole. *European Journal of Endocrinology*, **2015**, 172, 473-81	6.5	67
155	Ovarian macrocysts and gonadotrope-ovarian axis disruption in premenopausal women receiving mitotane for adrenocortical carcinoma or Cushing's disease. *European Journal of Endocrinology*, **2015**, 172, 141-9	6.5	14

154	Post-surgical management of non-functioning pituitary adenoma. *Annales DlEndocrinologie*, **2015**, 76, 228-38	1.7	44
153	Long-term effects of pegvisomant on comorbidities in patients with acromegaly: a retrospective single-center study. *European Journal of Endocrinology*, **2015**, 173, 693-702	6.5	32
152	Pituitary Apoplexy. *Endocrine Reviews*, **2015**, 36, 622-45	27.2	183
151	Pituitary apoplexy. *Endocrinology and Metabolism Clinics of North America*, **2015**, 44, 199-209	5.5	37
150	Genetic mutations in sporadic pituitary adenomas--what to screen for?. *Nature Reviews Endocrinology*, **2015**, 11, 43-54	15.2	66
149	New insights in prolactin: pathological implications. *Nature Reviews Endocrinology*, **2015**, 11, 265-75	15.2	133
148	Pegvisomant treatment in patients with acromegaly in clinical practice: The French ACROSTUDY. *Annales DlEndocrinologie*, **2015**, 76, 664-70	1.7	19
147	Expert consensus document: A consensus on the medical treatment of acromegaly. *Nature Reviews Endocrinology*, **2014**, 10, 243-8	15.2	255
146	Insulin-like peptide 3 (INSL3) in men with congenital hypogonadotropic hypogonadism/Kallmann syndrome and effects of different modalities of hormonal treatment: a single-center study of 281 patients. *Journal of Clinical Endocrinology and Metabolism*, **2014**, 99, E268-75	5.6	34
145	Ketoconazole in Cushing's disease: is it worth a try?. *Journal of Clinical Endocrinology and Metabolism*, **2014**, 99, 1623-30	5.6	188
144	Growth hormone, insulin-like growth factor-1, and the kidney: pathophysiological and clinical implications. *Endocrine Reviews*, **2014**, 35, 234-81	27.2	131
143	Acromegaly. *Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn*, **2014**, 124, 197-219	3	31
142	Impact of successful treatment of acromegaly on overnight heart rate variability and sleep apnea. *Journal of Clinical Endocrinology and Metabolism*, **2014**, 99, 2925-31	5.6	30
141	Acromegaly and McCune-Albright syndrome. *Journal of Clinical Endocrinology and Metabolism*, **2014** , 99, 1955-69	5.6	104
140	Hepato-pancreato-biliary lesions are present in both Carney complex and McCune Albright syndrome: comments on P. Salpea and C. Stratakis. *Molecular and Cellular Endocrinology*, **2014**, 382, 344-345	4.4	7
139	Prevalence and risk factors of impaired glucose tolerance and diabetes mellitus at diagnosis of acromegaly: a study in 148 patients. *Pituitary*, **2014**, 17, 81-9	4.3	78
138	Cardiac structure and function in Cushing's syndrome: a cardiac magnetic resonance imaging study. *Journal of Clinical Endocrinology and Metabolism*, **2014**, 99, E2144-53	5.6	45
137	Hepatobiliary and Pancreatic neoplasms in patients with McCune-Albright syndrome. *Journal of Clinical Endocrinology and Metabolism*, **2014**, 99, E97-101	5.6	58

136	Gigantism and acromegaly due to Xq26 microduplications and GPR101 mutation. *New England Journal of Medicine*, **2014**, 371, 2363-74	59.2	220
135	Lessons from McCune-Albright syndrome-associated intraductal papillary mucinous neoplasms: : GNAS-activating mutations in pancreatic carcinogenesis. *JAMA Surgery*, **2014**, 149, 858-62	5.4	29
134	Management of hyperglycaemia in Cushing@ disease: expertsQproposals on the use of pasireotide. *Diabetes and Metabolism*, **2013**, 39, 34-41	5.4	49
133	Frequent large germline HRPT2 deletions in a French National cohort of patients with primary hyperparathyroidism. *Journal of Clinical Endocrinology and Metabolism*, **2013**, 98, E403-8	5.6	86
132	Goals of treatment **2013**, 68-76		0
131	Computed tomography of the anterior skull base in Kallmann syndrome reveals specific ethmoid bone abnormalities associated with olfactory bulb defects. *Journal of Clinical Endocrinology and Metabolism*, **2013**, 98, E537-46	5.6	24
130	Primary hyperparathyroidism in pregnancy. *Endocrine*, **2013**, 44, 591-7	4	53
129	Higher risk of death among MEN1 patients with mutations in the JunD interacting domain: a Groupe d@tude des Tumeurs Endocrines (GTE) cohort study. *Human Molecular Genetics*, **2013**, 22, 1940-8	5.6	68
128	Growth hormone effects on cortical bone dimensions in young adults with childhood-onset growth hormone deficiency. *Osteoporosis International*, **2012**, 23, 2219-26	5.3	18
127	GNAS-activating mutations define a rare subgroup of inflammatory liver tumors characterized by STAT3 activation. *Journal of Hepatology*, **2012**, 56, 184-91	13.4	298
126	Clinical characteristics and outcome of acromegaly induced by ectopic secretion of growth hormone-releasing hormone (GHRH): a French nationwide series of 21 cases. *Journal of Clinical Endocrinology and Metabolism*, **2012**, 97, 2093-104	5.6	57
125	Prolactinomas resistant to standard doses of cabergoline: a multicenter study of 92 patients. *European Journal of Endocrinology*, **2012**, 167, 651-62	6.5	130
124	Cardiovascular findings and management in Turner syndrome: insights from a French cohort. *European Journal of Endocrinology*, **2012**, 167, 517-22	6.5	27
123	MAX mutations cause hereditary and sporadic pheochromocytoma and paraganglioma. *Clinical Cancer Research*, **2012**, 18, 2828-37	12.9	226
122	Pathophysiology of renal calcium handling in acromegaly: what lies behind hypercalciuria?. *Journal of Clinical Endocrinology and Metabolism*, **2012**, 97, 2124-33	5.6	37
121	No evidence of a detrimental effect of cabergoline therapy on cardiac valves in patients with acromegaly. *Journal of Clinical Endocrinology and Metabolism*, **2012**, 97, E1714-9	5.6	47
120	High-dose mitotane strategy in adrenocortical carcinoma: prospective analysis of plasma mitotane measurement during the first 3 months of follow-up. *European Journal of Endocrinology*, **2012**, 166, 261-8	6.5	44
119	Germline AIP mutations in apparently sporadic pituitary adenomas: prevalence in a prospective single-center cohort of 443 patients. *Journal of Clinical Endocrinology and Metabolism*, **2012**, 97, E663-70	5.6	114

118	Treatment of neurogenic diabetes insipidus. *Annales DlEndocrinologie*, **2011**, 72, 496-9	1.7	13
117	Mitotane, metyrapone, and ketoconazole combination therapy as an alternative to rescue adrenalectomy for severe ACTH-dependent Cushing's syndrome. *Journal of Clinical Endocrinology and Metabolism*, **2011**, 96, 2796-804	5.6	148
116	Estradiol levels in men with congenital hypogonadotropic hypogonadism and the effects of different modalities of hormonal treatment. *Fertility and Sterility*, **2011**, 95, 2324-9, 2329.e1-3	4.8	25
115	Integrated genomic profiling identifies loss of chromosome 11p impacting transcriptomic activity in aggressive pituitary PRL tumors. *Brain Pathology*, **2011**, 21, 533-43	6	35
114	Diabetes in acromegaly, prevalence, risk factors, and evolution: data from the French Acromegaly Registry. *European Journal of Endocrinology*, **2011**, 164, 877-84	6.5	113
113	Current management practices for acromegaly: an international survey. *Pituitary*, **2011**, 14, 125-33	4.3	72
112	Body fluid expansion in acromegaly is related to enhanced epithelial sodium channel (ENaC) activity. *Journal of Clinical Endocrinology and Metabolism*, **2011**, 96, 2127-35	5.6	35
111	AIP mutation in pituitary adenomas. *New England Journal of Medicine*, **2011**, 364, 1973-4; author reply 1974-5	59.2	17
110	Recurrent PRKAR1A mutation in acrodysostosis with hormone resistance. *New England Journal of Medicine*, **2011**, 364, 2218-26	59.2	140
109	Endocrine effects of the tyrosine kinase inhibitor vandetanib in patients treated for thyroid cancer. *Journal of Clinical Endocrinology and Metabolism*, **2011**, 96, 2741-9	5.6	42
108	Prevalence and incidence of diabetes mellitus in adult patients on growth hormone replacement for growth hormone deficiency: a surveillance database analysis. *Journal of Clinical Endocrinology and Metabolism*, **2011**, 96, 2255-61	5.6	54
107	The European Registry on Cushing's syndrome: 2-year experience. Baseline demographic and clinical characteristics. *European Journal of Endocrinology*, **2011**, 165, 383-92	6.5	234
106	Place of cabergoline in acromegaly: a meta-analysis. *Journal of Clinical Endocrinology and Metabolism*, **2011**, 96, 1327-35	5.6	191
105	Normosmic congenital hypogonadotropic hypogonadism due to TAC3/TACR3 mutations: characterization of neuroendocrine phenotypes and novel mutations. *PLoS ONE*, **2011**, 6, e25614	3.7	65
104	Prognostic markers of survival after combined mitotane- and platinum-based chemotherapy in metastatic adrenocortical carcinoma. *Endocrine-Related Cancer*, **2010**, 17, 797-807	5.7	43
103	Clinical characteristics and therapeutic responses in patients with germ-line AIP mutations and pituitary adenomas: an international collaborative study. *Journal of Clinical Endocrinology and Metabolism*, **2010**, 95, E373-83	5.6	259
102	A new FSHbeta mutation in a 29-year-old woman with primary amenorrhea and isolated FSH deficiency: functional characterization and ovarian response to human recombinant FSH. *European Journal of Endocrinology*, **2010**, 162, 633-41	6.5	44
101	A consensus on criteria for cure of acromegaly. *Journal of Clinical Endocrinology and Metabolism*, **2010**, 95, 3141-8	5.6	572

100	Non-syndromic congenital hypogonadotropic hypogonadism: clinical presentation and genotype-phenotype relationships. *European Journal of Endocrinology*, **2010**, 162, 835-51	6.5	89
99	Acromegaly and pregnancy: a retrospective multicenter study of 59 pregnancies in 46 women. *Journal of Clinical Endocrinology and Metabolism*, **2010**, 95, 4680-7	5.6	84
98	Factors predicting relapse of nonfunctioning pituitary macroadenomas after neurosurgery: a study of 142 patients. *European Journal of Endocrinology*, **2010**, 163, 193-200	6.5	126
97	TAC3 and TACR3 defects cause hypothalamic congenital hypogonadotropic hypogonadism in humans. *Journal of Clinical Endocrinology and Metabolism*, **2010**, 95, 2287-95	5.6	178
96	Metabolic syndrome in Cushing syndrome. *Neuroendocrinology*, **2010**, 92 Suppl 1, 96-101	5.6	73
95	Prevalence of metabolic syndrome in adult hypopituitary growth hormone (GH)-deficient patients before and after GH replacement. *Journal of Clinical Endocrinology and Metabolism*, **2010**, 95, 74-81	5.6	94
94	Congenital hypogonadotropic hypogonadism in females: clinical spectrum, evaluation and genetics. *Annales DlEndocrinologie*, **2010**, 71, 158-62	1.7	22
93	Ovarian dysfunction by activating mutation of GS alpha: McCune-Albright syndrome as a model. *Annales DlEndocrinologie*, **2010**, 71, 210-3	1.7	10
92	Female gonadal function before and after treatment of acromegaly. *Journal of Clinical Endocrinology and Metabolism*, **2010**, 95, 4518-25	5.6	63
91	Temozolomide treatment in aggressive pituitary tumors and pituitary carcinomas: a French multicenter experience. *Journal of Clinical Endocrinology and Metabolism*, **2010**, 95, 4592-9	5.6	178
90	Differential gene expression profiles of invasive and non-invasive non-functioning pituitary adenomas based on microarray analysis. *Endocrine-Related Cancer*, **2010**, 17, 361-71	5.7	63
89	Comparative validation of the growth hormone-releasing hormone and arginine test for the diagnosis of adult growth hormone deficiency using a growth hormone assay conforming to recent international recommendations. *Journal of Clinical Endocrinology and Metabolism*, **2010**, 95, 3684-92	5.6	19
88	Endocrine aspects of obstructive sleep apnea. *Journal of Clinical Endocrinology and Metabolism*, **2010**, 95, 483-95	5.6	150
87	Isolated familial hypogonadotropic hypogonadism and a GNRH1 mutation. *New England Journal of Medicine*, **2009**, 360, 2742-8	59.2	208
86	Long-term results of stereotactic radiosurgery in secretory pituitary adenomas. *Journal of Clinical Endocrinology and Metabolism*, **2009**, 94, 3400-7	5.6	137
85	Does attainment of target levels of growth hormone and insulin-like growth factor I improve acromegaly prognosis?. *Nature Clinical Practice Endocrinology and Metabolism*, **2009**, 5, 70-1		4
84	Cinacalcet reduces serum calcium concentrations in patients with intractable primary hyperparathyroidism. *Journal of Clinical Endocrinology and Metabolism*, **2009**, 94, 2766-72	5.6	111
83	Effects of somatostatin analogs on glucose homeostasis: a metaanalysis of acromegaly studies. *Journal of Clinical Endocrinology and Metabolism*, **2009**, 94, 1500-8	5.6	161

82	D3 GH receptor polymorphism is not associated with IGF1 levels in untreated acromegaly. *European Journal of Endocrinology*, **2009**, 161, 231-5	6.5	29
81	Mutational status of EGFR, BRAF, PI3KCA and JAK2 genes in endocrine tumors. *International Journal of Cancer*, **2009**, 124, 751-3	7.5	13
80	Pituitary tumours: acromegaly. *Best Practice and Research in Clinical Endocrinology and Metabolism*, **2009**, 23, 555-74	6.5	103
79	Classification et physiopathologie des adhomes hypophysaires. *Bulletin De LlAcademie Nationale De Medecine*, **2009**, 193, 1543-1556	0.1	
78	Pregnancy outcomes following cabergoline treatment: extended results from a 12-year observational study. *Clinical Endocrinology*, **2008**, 68, 66-71	3.4	98
77	Control of IGF-I levels with titrated dosing of lanreotide Autogel over 48 weeks in patients with acromegaly. *Clinical Endocrinology*, **2008**, 69, 299-305	3.4	62
76	Acromegaly. *Orphanet Journal of Rare Diseases*, **2008**, 3, 17	4.2	154
75	Primary amenorrhea revealing an occult progesterone-secreting ovarian tumor. *Fertility and Sterility*, **2008**, 90, 1198.e1-5	4.8	10
74	Emerging drugs for acromegaly. *Expert Opinion on Emerging Drugs*, **2008**, 13, 273-93	3.7	8
73	Epithelial sodium channel is a key mediator of growth hormone-induced sodium retention in acromegaly. *Endocrinology*, **2008**, 149, 3294-305	4.8	70
72	Kallmann syndrome: a comparison of the reproductive phenotypes in men carrying KAL1 and FGFR1/KAL2 mutations. *Journal of Clinical Endocrinology and Metabolism*, **2008**, 93, 758-63	5.6	89
71	Rapidly reversible myocardial edema in patients with acromegaly: assessment with ultrafast T2 mapping in a single-breath-hold MRI sequence. *American Journal of Roentgenology*, **2008**, 190, 1576-82	5.4	32
70	Dynamic tests for the diagnosis and assessment of treatment efficacy in acromegaly. *Pituitary*, **2008**, 11, 129-39	4.3	23
69	Benign cortisol-secreting adrenocortical adenomas produce small amounts of androgens. *Clinical Endocrinology*, **2007**, 66, 778-88	3.4	12
68	Cardiac effects of growth hormone treatment in chronic heart failure: A meta-analysis. *Journal of Clinical Endocrinology and Metabolism*, **2007**, 92, 180-5	5.6	59
67	Impact of somatostatin analogs on the heart in acromegaly: a metaanalysis. *Journal of Clinical Endocrinology and Metabolism*, **2007**, 92, 1743-7	5.6	115
66	Germline inactivating mutations of the aryl hydrocarbon receptor-interacting protein gene in a large cohort of sporadic acromegaly: mutations are found in a subset of young patients with macroadenomas. *European Journal of Endocrinology*, **2007**, 157, 1-8	6.5	110
65	McCune-Albright syndrome in adulthood. *Pediatric Endocrinology Reviews*, **2007**, 4 Suppl 4, 453-62	1.1	9

64	A PRKAR1A mutation associated with primary pigmented nodular adrenocortical disease in 12 kindreds. *Journal of Clinical Endocrinology and Metabolism*, **2006**, 91, 1943-9	5.6	96
63	McCune-Albright syndrome and acromegaly: effects of hypothalamopituitary radiotherapy and/or pegvisomant in somatostatin analog-resistant patients. *Journal of Clinical Endocrinology and Metabolism*, **2006**, 91, 4957-61	5.6	50
62	Less is more risky? Growth hormone and insulin-like growth factor 1 levels and cardiovascular risk. *Nature Clinical Practice Endocrinology and Metabolism*, **2006**, 2, 650-1		8
61	Pituitary tumour transforming gene (PTTG) expression correlates with the proliferative activity and recurrence status of pituitary adenomas: a clinical and immunohistochemical study. *Clinical Endocrinology*, **2006**, 65, 536-43	3.4	118
60	Outcome of gamma knife radiosurgery in 82 patients with acromegaly: correlation with initial hypersecretion. *Journal of Clinical Endocrinology and Metabolism*, **2005**, 90, 4483-8	5.6	188
59	Comparison of fast Fourier transform and autoregressive spectral analysis for the study of heart rate variability in diabetic patients. *International Journal of Cardiology*, **2005**, 104, 307-13	3.2	53
58	Testicular anti-mullerian hormone secretion is stimulated by recombinant human FSH in patients with congenital hypogonadotropic hypogonadism. *Journal of Clinical Endocrinology and Metabolism*, **2005**, 90, 724-8	5.6	98
57	Gross total resection or debulking of pituitary adenomas improves hormonal control of acromegaly by somatostatin analogs. *European Journal of Endocrinology*, **2005**, 152, 61-6	6.5	123
56	A critical analysis of pituitary tumor shrinkage during primary medical therapy in acromegaly. *Journal of Clinical Endocrinology and Metabolism*, **2005**, 90, 4405-10	5.6	168
55	Type A insulin resistance syndrome revealing a novel lamin A mutation. *Diabetes*, **2005**, 54, 1873-8	0.9	60
54	Impact of growth hormone (GH) treatment on cardiovascular risk factors in GH-deficient adults: a Metaanalysis of Blinded, Randomized, Placebo-Controlled Trials. *Journal of Clinical Endocrinology and Metabolism*, **2004**, 89, 2192-9	5.6	265
53	Long-term outcome of patients with acromegaly and congestive heart failure. *Journal of Clinical Endocrinology and Metabolism*, **2004**, 89, 5308-13	5.6	75
52	Parental origin of Gsalpha mutations in the McCune-Albright syndrome and in isolated endocrine tumors. *Journal of Clinical Endocrinology and Metabolism*, **2004**, 89, 3007-9	5.6	55
51	Pituitary magnetic resonance imaging findings do not influence surgical outcome in adrenocorticotropin-secreting microadenomas. *Journal of Clinical Endocrinology and Metabolism*, **2004**, 89, 3371-6	5.6	76
50	Management of pituitary apoplexy. *Expert Opinion on Pharmacotherapy*, **2004**, 5, 1287-98	4	39
49	Pituitary Incidentalomas **2003**, 13, 124-135		14
48	Severe hyponatremia as a frequent revealing sign of hypopituitarism after 60 years of age. *European Journal of Endocrinology*, **2003**, 149, 177-8	6.5	27
47	Chromogranin A as serum marker of pituitary adenomas. *Clinical Endocrinology*, **2003**, 59, 644-8	3.4	10

46	Hypogonadotropic hypogonadism as a model of post-natal testicular anti-Müllerian hormone secretion in humans. *Molecular and Cellular Endocrinology*, **2003**, 211, 51-4	4.4	23
45	Cardiac effects of growth hormone in adults with growth hormone deficiency: a meta-analysis. *Circulation*, **2003**, 108, 2648-52	16.7	132
44	Normal pituitary hypertrophy as a frequent cause of pituitary incidentaloma: a follow-up study. *Journal of Clinical Endocrinology and Metabolism*, **2001**, 86, 3009-15	5.6	86
43	Efficacy of the long-acting octreotide formulation (octreotide-LAR) in patients with thyrotropin-secreting pituitary adenomas. *Journal of Clinical Endocrinology and Metabolism*, **2001**, 86, 2849-53	5.6	98
42	Impact of Growth Hormone-Lowering Treatments on Heart Function in Acromegaly. *Growth Hormone*, **2001**, 45-57		1
41	Vascular reactivity in acromegalic patients: preliminary evidence for regional endothelial dysfunction and increased sympathetic vasoconstriction. *Clinical Endocrinology*, **2000**, 53, 445-51	3.4	56
40	Efficacy and tolerability of the long-acting somatostatin analog lanreotide in acromegaly. A 12-month multicenter study of 58 acromegalic patients. French Multicenter Study Group on Lanreotide in Acromegaly. *Pituitary*, **2000**, 2, 269-76	4.3	32
39	Time course of GH and IGF-1 levels following withdrawal of long-acting octreotide in acromegaly. *Pituitary*, **2000**, 3, 193-7	4.3	20
38	Effects of human recombinant luteinizing hormone and follicle-stimulating hormone in patients with acquired hypogonadotropic hypogonadism: study of Sertoli and Leydig cell secretions and interactions. *Journal of Clinical Endocrinology and Metabolism*, **2000**, 85, 3239-44	5.6	63
37	The antigonadotropic activity of a 19-nor-progesterone derivative is exerted both at the hypothalamic and pituitary levels in women. *Journal of Clinical Endocrinology and Metabolism*, **1999**, 84, 4191-6	5.6	49
36	Antimüllerian hormone in patients with hypogonadotropic hypogonadism. *Journal of Clinical Endocrinology and Metabolism*, **1999**, 84, 2696-9	5.6	70
35	Functional hypothalamic amenorrhoea: a partial and reversible gonadotrophin deficiency of nutritional origin. *Clinical Endocrinology*, **1999**, 50, 229-35	3.4	81
34	Biochemical characterization of a Ca2+/NAD(P)H-dependent H2O2 generator in human thyroid tissue. *Biochimie*, **1999**, 81, 373-80	4.6	54
33	Antimullerian Hormone in Patients with Hypogonadotropic Hypogonadism. *Journal of Clinical Endocrinology and Metabolism*, **1999**, 84, 2696-2699	5.6	60
32	Decreased regional blood flow in patients with acromegaly. *Clinical Endocrinology*, **1998**, 49, 725-31	3.4	32
31	Germ-line mutation analysis in patients with multiple endocrine neoplasia type 1 and related disorders. *American Journal of Human Genetics*, **1998**, 63, 455-67	11	178
30	Absence of activating mutations in the GnRH receptor gene in human pituitary gonadotroph adenomas. *European Journal of Endocrinology*, **1998**, 139, 157-60	6.5	20
29	Growth hormone as a risk for premature mortality in healthy subjects: data from the Paris prospective study. *BMJ: British Medical Journal*, **1998**, 316, 1132-3		56

28	Pitfall of Petrosal Sinus Sampling in a Cushing's Syndrome Secondary to Ectopic Adrenocorticotropin-Corticotropin Releasing Hormone (ACTH-CRH) Secretion. *Journal of Clinical Endocrinology and Metabolism*, **1998**, 83, 305-308	5.6	41
27	Panhypopituitarism as a model to study the metabolism of dehydroepiandrosterone (DHEA) in humans. *Journal of Clinical Endocrinology and Metabolism*, **1997**, 82, 2578-85	5.6	109
26	Free luteinizing-hormone beta-subunit in normal subjects and patients with pituitary adenomas. *Journal of Clinical Endocrinology and Metabolism*, **1997**, 82, 1397-402	5.6	24
25	A family with hypogonadotropic hypogonadism and mutations in the gonadotropin-releasing hormone receptor. *New England Journal of Medicine*, **1997**, 337, 1597-602	59.2	413
24	Predicting the effects of long-term medical treatment in acromegaly. At what cost? For what benefits?. *European Journal of Endocrinology*, **1997**, 136, 359-61	6.5	6
23	Panhypopituitarism as a Model to Study the Metabolism of Dehydroepiandrosterone (DHEA) in Humans. *Journal of Clinical Endocrinology and Metabolism*, **1997**, 82, 2578-2585	5.6	81
22	The antigonadotropic activity of progestins (19-nortestosterone and 19- norprogesterone derivatives) is not mediated through the androgen receptor. *Journal of Clinical Endocrinology and Metabolism*, **1996**, 81, 4218-4223	5.6	16
21	Osteoblastic cells derived from isolated lesions of fibrous dysplasia contain activating somatic mutations of the Gs alpha gene. *Human Molecular Genetics*, **1995**, 4, 1675-6	5.6	62
20	Even after priming with ovarian steroids or pulsatile gonadotropin- releasing hormone administration, naltrexone is unable to induce ovulation in women with functional hypothalamic amenorrhea. *Journal of Clinical Endocrinology and Metabolism*, **1995**, 80, 2102-2107	5.6	14
19	Thyrotropin-releasing hormone (TRH) binding sites and thyrotropin response to TRH are regulated by thyroid hormones in human thyrotropic adenomas. *European Journal of Endocrinology*, **1994**, 130, 559-64	6.5	11
18	The diagnostic value of fine-needle aspiration biopsy under ultrasonography in nonfunctional thyroid nodules: a prospective study comparing cytologic and histologic findings. *American Journal of Medicine*, **1994**, 97, 152-7	2.4	107
17	McCune-Albright syndrome and acromegaly: clinical studies and responses to treatment in five cases. *European Journal of Endocrinology*, **1994**, 131, 229-34	6.5	80
16	Hyperfunctioning unilateral adrenal macronodule in three patients with Cushing's disease: hormonal and imaging characterization. *European Journal of Endocrinology*, **1993**, 129, 284-90	6.5	8
15	Clinical pharmacokinetics of octreotide. Therapeutic applications in patients with pituitary tumours. *Clinical Pharmacokinetics*, **1993**, 25, 375-91	6.2	85
14	Non-responsiveness of serum gonadotropins and testosterone to pulsatile GnRH in hemochromatosis suggesting a pituitary defect. *European Journal of Endocrinology*, **1993**, 128, 351-4	6.5	30
13	Octreotide therapy for thyroid-stimulating hormone-secreting pituitary adenomas. A follow-up of 52 patients. *Annals of Internal Medicine*, **1993**, 119, 236-40	8	145
12	Inhibin and follicle-stimulating hormone levels in gonadotroph adenomas: evidence of a positive correlation with tumour volume in men. *Clinical Endocrinology*, **1993**, 38, 301-9	3.4	28
11	Resistance to somatostatin (SRIH) analog therapy in acromegaly. Re-evaluation of the correlation between the SRIH receptor status of the pituitary tumor and the in vivo inhibition of GH secretion in response to SRIH analog. *Hormone Research*, **1992**, 38, 94-9		14

10	Heart failure and octreotide in acromegaly. *Lancet, The*, **1992**, 339, 242-3	40	4
9	Shrinkage of a primary thyrotropin-secreting pituitary adenoma treated with the long-acting somatostatin analogue octreotide (SMS 201-995). *European Journal of Endocrinology*, **1991**, 124, 487-91	6.5	20
8	Cardiovascular effects of the somatostatin analog octreotide in acromegaly. *Annals of Internal Medicine*, **1990**, 113, 921-5	8	88
7	Pituitary granuloma and pyoderma gangrenosum. *Journal of Endocrinological Investigation*, **1990**, 13, 677-81	5.2	12
6	The effect of somatostatin analogue on chiasmal dysfunction from pituitary macroadenomas. *Journal of Neurosurgery*, **1989**, 71, 687-90	3.2	39
5	Torsade de pointes and Q-T prolongation in secondary hypothyroidism. *Lancet, The*, **1988**, 2, 170-1	40	6
4	Management of early postoperative diabetes insipidus with parenteral desmopressin. *European Journal of Endocrinology*, **1988**, 117, 513-6	6.5	8
3	The effect of subcutaneous infusion versus subcutaneous injections of a somatostatin analogue (SMS 201-995) on the diurnal GH profile in acromegaly. *European Journal of Endocrinology*, **1987**, 116, 108-12	6.5	22
2	Rapid improvement in sleep apnoea of acromegaly after short-term treatment with somatostatin analogue SMS 201-995. *Lancet, The*, **1986**, 1, 1270-1	40	33
1	Effects of Human Recombinant Luteinizing Hormone and Follicle-Stimulating Hormone in Patients with Acquired Hypogonadotropic Hypogonadism: Study of Sertoli and Leydig Cell Secretions and Interactions		17